

1 SHIRLI FABBRI WEISS (Bar No. 079225)  
shirli.weiss@dlapiper.com  
2 GERARD A. TRIPPITELLI (Bar No. 235788)  
jerry.trippitelli@dlapiper.com  
3 JULIE L. SCHWARTZ (Bar No. 216392)  
julie.schwartz@dlapiper.com  
4 ALYSSON RUSSELL SNOW (Bar No. 225185)  
alysson.snow@dlapiper.com  
5 **DLA PIPER US LLP**  
401 B Street, Suite 1700  
6 San Diego, CA 92101-4297  
Tel: 619.699.3650  
7 Fax: 619.699.2701

8  
9 Attorneys for Defendant  
ALEXANDER YAROSHINSKY

10

11 UNITED STATES DISTRICT COURT  
12 NORTHERN DISTRICT OF CALIFORNIA

13 IN RE CONNETICS CORPORATION  
14 SECURITIES LITIGATION

15 \_\_\_\_\_  
16 This Document Relates To:

17 ALL ACTIONS.  
18 \_\_\_\_\_  
19  
20

CASE NO. 3:07-cv-02940-SI

CLASS ACTION

**ALEXANDER YAROSHINSKY'S REPLY  
IN SUPPORT OF HIS MOTION TO  
DISMISS PLAINTIFF'S SECOND  
AMENDED CONSOLIDATED CLASS  
ACTION COMPLAINT**

Date: August 15, 2008  
Courtroom: 10  
Time: 9:00 a.m.  
Judge: Honorable Susan Illston

21

22

23

24

25

26

27

28

## **TABLE OF CONTENTS**

	Page	
2		
3	I. INTRODUCTION AND SUMMARY OF ARGUMENT .....	1
4	II. PLAINTIFF DOES NOT HAVE STANDING TO ASSERT CLAIMS AGAINST	
5	DR. YAROSHINSKY .....	3
6	A. Plaintiff Did Not Trade Contemporaneously With Dr. Yaroshinsky.....	4
7	B. Plaintiff's Purported Contemporaneous Trades with Other Defendants	
8	Cannot Cure Plaintiff's Failure to Trade Contemporaneously with Dr.	
9	Yaroshinsky. ....	4
10	C. Other Class Members' Purported Trades Cannot Cure Plaintiff's Lack of	
11	Standing Arising From Its Failure to Trade Contemporaneously with Dr.	
12	Yaroshinsky. ....	5
13	D. Defendant Zak's Sales Cannot Be Imputed to Dr. Yaroshinsky and, Even if	
14	They Could, Plaintiff did not Trade Contemporaneously with Zak.....	7
15	1. Plaintiff's April 18 and 19 Trades Were Not Contemporaneous with	
16	Zak's April 13 Trades. ....	7
17	2. Zak's Unspecified Trades Between April 24 and June 10 Were Not	
18	Contemporaneous with Plaintiff's April 18 and 19 Trades. ....	10
19	III. THE COMPLAINT FAILS TO PLEAD A STRONG INFERENCE OF	
20	SCIENTER.....	12
21	IV. PLAINTIFF DID NOT STATE A CLAIM FOR TIPPER/TIPPEE LIABILITY .....	14
22	V. THE SECTION 20A CLAIM MUST BE DISMISSED ON OTHER GROUNDS.....	15
23	VI. CONCLUSION .....	15

**TABLE OF AUTHORITIES**

	<u>Page</u>
CASES	
<i>Brody v. Transitional Hosps. Corp.</i> , 280 F.3d 997 (9th Cir. 2002).....	3, 5, 6, 7
<i>Buban v. O'Brien</i> , 1994 WL 324093 (N.D. Cal. June 22, 1994) .....	7, 8, 10
<i>In re AST Research Sec. Litig.</i> , 887 F. Supp. 231 (C.D. Cal. 1995).....	9
<i>In re Cendant Corp. Litig.</i> , 60 F. Supp. 2d 354 (D.N.J. 1999) .....	7
<i>In re Connetics Corp. Sec. Litig.</i> , 542 F. Supp. 2d 996 (N.D. Cal. 2008) .....	5
<i>In re Countrywide Fin. Corp. Deriv. Litig.</i> , 542 F. Supp. 2d 1160 (C.D. Cal. 2008) .....	11
<i>In re Countrywide Financial Corp. Deriv. Litig.</i> , 2008 U.S. Dist. LEXIS 40754 (C.D. Cal. May 14, 2008) .....	9, 11
<i>In re Eng'g Animation Sec. Litig.</i> , 110 F. Supp. 2d 1183 (S.D. Iowa 2000) .....	10
<i>In re Enron Corp. Sec., Deriv. &amp; ERISA Litig.</i> , 258 F. Supp. 2d 576 (S.D. Tex. 2003) .....	10
<i>In re Genentech, Inc. Sec. Litig.</i> , 1989 WL 201577 (N.D. Cal. Dec. 11, 1989) .....	5, 11
<i>In re MicroStrategy, Inc. Sec. Litig.</i> , 115 F. Supp. 2d 620 (E.D. Va. 2000).....	5
<i>In re Oxford Health Plans, Inc. Sec. Litig.</i> , 187 F.R.D. 133 (S.D.N.Y. 1999) .....	9, 10
<i>In re Qwest Communs. Int'l Sec. Litig.</i> , 396 F. Supp. 2d 1178 (D. Colo. 2004).....	11
<i>In re Verifone Sec. Litig.</i> , 784 F. Supp. 1471 (N.D. Cal. 1992), <i>aff'd</i> , 11 F.3d 865 (9th Cir. 1993) .....	4, 5, 10
<i>In re Waldus Sec. Litig.</i> , 993 WL 121478 (W.D. Wash. Mar. 1, 1993) .....	5
<i>In re Wet Seal, Inc. Sec. Litig.</i> , 518 F. Supp. 2d 1148 (C.D. Cal. 2007) .....	11

**TABLE OF CONTENTS**  
**(continued)**

	<u>Page</u>
2	
3	<i>Middlesex Ret. Sys. v. Quest Software</i> , 527 F. Supp. 2d 1164 (C.D. Cal. 2007) ..... 6, 7, 8, 9, 10
4	
5	<i>Middlesex Ret. Sys. v. Quest Software, Inc.</i> , No. CV 06-6863 (C.D. Cal. July 10, 2008) ..... 6, 9
6	
7	<i>Neubronner v. Milken</i> , 6 F.3d 666 (9th Cir. 1993)..... passim
8	
9	<i>O'Shea v. Littleton</i> , 414 U.S. 488 (1974)..... 5
10	
11	<i>Openwave Systems Sec. Litig.</i> , 528 F. Supp. 2d 236 (S.D.N.Y. 2007)..... 6
12	
13	<i>Shurkin v. Golden State Vintners Inc.</i> , 471 F. Supp. 2d 998 (N.D. Cal. 2006) ..... 11, 15
14	
15	<i>Wilson v. Comtech Telecommunications Corp.</i> , 648 F.2d 88 (2d Cir. 1988)..... 7, 8, 9

## **STATUTES**

14	15 U.S.C. §§ 78j(b), <i>et seq.</i> .....	3
15	15 U.S.C. § 78t-1(a) .....	3
16	15 U.S.C. § 78t-1(b)(2) .....	8
17	15 U.S.C. § 78u-4(a)(1) .....	14
18	15 U.S.C. § 78u-4(b)(3)(A).....	13
19	15 U.S.C. § 78u-4(b)(3)(B).....	11

1       **I. INTRODUCTION AND SUMMARY OF ARGUMENT**

2              As established in Dr. Yaroshinsky's Opening Brief in support of his Motion to Dismiss,  
 3 Plaintiff, for the *third time*, fails to state a claim against him for violation of Section 10(b) and  
 4 Section 20A of the Securities Exchange Act of 1934 for two independent reasons: (1) Plaintiff  
 5 does not have standing because it failed to plead that Plaintiff and Dr. Yaroshinsky  
 6 contemporaneously traded in Connetics' stock; and (2) Plaintiff failed to sufficiently plead that  
 7 Dr. Yaroshinsky acted with the requisite scienter, an essential element of Plaintiff's Section 10(b)  
 8 claim, in pleading its narrow insider trading claim against Dr. Yaroshinsky. The Opening Brief  
 9 also established that Plaintiff failed to sufficiently plead its Section 20A claims against Dr.  
 10 Yaroshinsky for two additional reasons: (1) the predicate violation to Plaintiff's Section 20A  
 11 claim is a properly pled Section 10(b) claim and Plaintiff failed to sufficiently plead its Section  
 12 10(b) claim against Dr. Yaroshinsky; and (2) Section 20A expressly precludes Plaintiff's  
 13 requested relief. In its Opposition Brief, Plaintiff fails to respond to these showings and, instead  
 14 (1) misapplies this Court's January 29, 2008 Order as to Dr. Yaroshinsky; (2) completely ignores  
 15 authority in this District, the Central District and other Districts cited by Dr. Yaroshinsky in his  
 16 Opening Brief; and (3) asserts conclusory arguments without citing any authority.

17              More specifically, Dr. Yaroshinsky's motion to dismiss should be granted for each of the  
 18 following reasons.

19              First, Plaintiff fails to overcome Dr. Yaroshinsky's showing in his Opening Brief that  
 20 Plaintiff lacks standing to assert its claims against Dr. Yaroshinsky. Plaintiff does not and cannot  
 21 address Dr. Yaroshinsky's showing, based on well-settled Ninth Circuit law, that Plaintiff cannot  
 22 have standing as to Dr. Yaroshinsky because Plaintiff traded *before* Dr. Yaroshinsky. Plaintiff  
 23 also ignores Dr. Yaroshinsky's showing that, even if it had adequately pled the other elements of  
 24 its theory of tipper/tippee liability based on alleged communications between Dr. Yaroshinsky and  
 25 Zak (which it has not), Plaintiff cannot establish standing by imputing Zak's trades to Dr.  
 26 Yaroshinsky because Plaintiff's trades were not contemporaneous with Zak's trades. As  
 27 explained below, Plaintiff's argument that the Court should adopt a blanket rule that all trades  
 28 made before the disclosure of alleged material non-public information are contemporaneous for

1 purposes of its insider trading claim, is contrary to the law in the Northern District as well as the  
2 law in other districts, is inconsistent with the Ninth Circuit's mandate that the contemporaneous  
3 trading requirement be narrowly construed and is inconsistent with the Second Circuit law that the  
4 Ninth Circuit followed in adopting the contemporaneous trading standard. Thus, the better rule,  
5 and that followed by numerous courts and cited by Dr. Yaroshinsky, is that trades must occur on  
6 the same day to be contemporaneous or, in the alternative, that the Court consider the volume of  
7 trading on the day that the defendant traded and the difference in the stock price on the day the  
8 defendant and plaintiff traded to determine if the sales were contemporaneous. Under either of  
9 these rules, Plaintiff did not contemporaneously trade with Zak and thus Zak's trades cannot give  
10 rise to standing to assert insider trading claims against Dr. Yaroshinsky. In a last ditch bid to  
11 establish standing, Plaintiff makes a failed attempt to argue that this Court's earlier ruling that  
12 Plaintiff has Article III standing with respect to its non-insider trading claims against the other  
13 defendants also establishes that it has standing with respect to its insider trading claims against Dr.  
14 Yaroshinsky. Not only was the Court's earlier ruling limited to the other defendants and the non-  
15 insider trading claims, but the Ninth Circuit has stated that the contemporaneous trading standing  
16 requirement is derived from judicially imposed limitations, *not* derived from Article III.

17       Second, Plaintiff fails to refute Dr. Yaroshinsky's showing in the Opening Brief that  
18 Plaintiff has not sufficiently pled a strong inference of scienter. Plaintiff cannot overcome the  
19 fact that the most compelling inference arising from Connexis' April 26, 2005 press release and  
20 earnings call is that by April 26, 2005 Dr. Yaroshinsky believed that he did not possess any  
21 material non-public information and could trade without violating the securities laws – i.e., that  
22 he did not act with scienter. As explained below, Plaintiff's argument that the Court has indicated  
23 in its earlier ruling that the April 26, 2005 disclosure might not have been complete does not  
24 undermine the compelling inference that Dr. Yaroshinsky thought all material non-public  
25 information had been disclosed. Nor does Plaintiff's list of purported scienter allegations  
26 scattered throughout the Second Amended Complaint (the "Complaint") plead a strong inference  
27 of scienter, and Plaintiff cites no authority to the contrary.

28 //

1           Third, Plaintiff does not sufficiently respond to Dr. Yaroshinsky's showing that, even if  
 2 Plaintiff pled that Plaintiff traded contemporaneously with Zak and Plaintiff had sufficiently pled  
 3 scienter (which it cannot), Plaintiff has failed to sufficiently plead facts showing tipper/tippee  
 4 liability, which it asserts as a part of its Section 20A claim. Plaintiff's allegations that Dr.  
 5 Yaroshinsky benefited from the alleged tip, which is a requisite element of any Section 20A  
 6 claim, is purely conclusory and based solely on its unsupported allegation that Zak was Dr.  
 7 Yaroshinsky's "friend." Contrary to Plaintiff's contention, this conclusory allegation does not  
 8 satisfy the Private Securities Litigation Reform Act's (the "Reform Act") requirement that  
 9 Plaintiff plead all elements of its claims against Dr. Yaroshinsky with specificity. Not  
 10 surprisingly, all of the cases Plaintiff cites were filed by the SEC, which, in alleging claims, is not  
 11 required to comport with the Reform Act's heightened pleading standard.

12           Finally, Plaintiff fails to adequately address Dr. Yaroshinsky's showing that Plaintiff's  
 13 Section 20A claim must be dismissed because it has failed to sufficiently plead its Section 10(b)  
 14 claims against Dr. Yaroshinsky, which is the requisite predicate violation on which Plaintiff's  
 15 Section 20A claim is based. Plaintiff's argument is that it has sufficiently pled its Section 10(b)  
 16 claim because Plaintiff says it has. Clearly, this is not enough. Moreover, Plaintiff cannot refute  
 17 that its relief for its alleged Section 20A violation must be limited to disgorgement. Plaintiff's  
 18 Section 20A claim should be dismissed for this independent reason as well.

19           For these reasons, Dr. Yaroshinsky respectfully requests that the Court grant his motion to  
 20 dismiss with prejudice.

21           **II. PLAINTIFF DOES NOT HAVE STANDING TO ASSERT CLAIMS AGAINST DR.  
 22 YAROSHINSKY**

23           It is well-settled that in order to have standing to bring its Section 10(b) and Section 20A  
 24 claims against Dr. Yaroshinsky based on insider trading claims, Plaintiff must plead specific facts  
 25 that it traded contemporaneously with Dr. Yaroshinsky. 15 U.S.C. §§ 78j(b), *et seq.* (2000)  
 26 (Section 10(b)); 15 U.S.C. § 78t-1(a) (2000) (Section 20A); *Brody v. Transitional Hosps. Corp.*,  
 27 280 F.3d 997, 1001 (9th Cir. 2002); *Neubronner v. Milken*, 6 F.3d 666, 669-70 (9th Cir. 1993).  
 28 As Dr. Yaroshinsky established in his Opening Brief, Plaintiff has failed to plead any such

1 contemporaneous trades. In the Opposition Brief, Plaintiff fails to refute this showing.

2           **A. Plaintiff Did Not Trade Contemporaneously With Dr. Yaroshinsky.**

3           Where a plaintiff's trades are before the alleged insider's trades, the trades cannot be  
 4 "contemporaneous." *In re Verifone Sec. Litig.*, 784 F. Supp. 1471, 1489 (N.D. Cal. 1992) ("No  
 5 liability can attach for trades made by plaintiffs before the insider engages in trading activity"),  
 6 *aff'd*, 11 F.3d 865 (9th Cir. 1993). As Dr. Yaroshinsky established in his Opening Brief, Plaintiff  
 7 cannot, as a matter of law, plead the requisite contemporaneous trading because Plaintiff's alleged  
 8 trades occurred *before* Dr. Yaroshinsky's alleged trades – Plaintiff traded only on April 18 and  
 9 19, 2005 and Dr. Yaroshinsky did not make his first trade until April 21, 2005. Opening Br. at  
 10 10:1-11:2. Plaintiff concedes as much, and in its Opposition does not even attempt to respond to  
 11 this fatal defect in the Complaint. *See* Opposition Br. at 46:16-47:9.

12           **B. Plaintiff's Purported Contemporaneous Trades with Other Defendants  
 13 Cannot Cure Plaintiff's Failure to Trade Contemporaneously with Dr.  
 14 Yaroshinsky.**

15           In an attempt to mask its lack of contemporaneous trades, and recognizing that it cannot  
 16 base its standing on Dr. Yaroshinsky's trades, Plaintiff argues that so long as it traded  
 17 contemporaneously with another Defendant, here Higgins, "Lead Plaintiff has standing to  
 18 represent the remainder of the plaintiff class in bringing § 20A claims against all of the § 20A  
 19 Defendants," including Dr. Yaroshinsky, even if it did not trade contemporaneously with Dr.  
 20 Yaroshinsky. (Opposition Br. at 45:16-46:13.)<sup>1</sup> Plaintiff's argument is based on a  
 21 misinterpretation of this Court's earlier ruling on the other defendants' motion to dismiss which  
 22 does not apply to Plaintiff's standing for its claims against Dr. Yaroshinsky for violation of  
 23 Section 10(b) and Section 20A claims for alleged insider trading.

24           First, the Ninth Circuit has held that the standing requirements for insider trading claims  
 25 under Section 10(b) are judicial standing limitations which "are not, of course of the  
 26 constitutional variety, grounded in Article III of the Constitution, but simply delineate the scope

---

27           <sup>1</sup> Plaintiff argues that the defendants have conceded that Plaintiff contemporaneously traded with  
 28 defendant Higgins. Neither Dr. Yaroshinsky nor any of the other defendants have made any such  
 concession. Moreover, Plaintiff's argument in this regard is independent of any attempt to impute Zak's  
 alleged contemporaneous sales to Dr. Yaroshinsky, which, as explained below, also fails.

1 of the implied cause of action.” *Brody*, 280 F.3d at 1000 n.3.

2 Second, the portion of the Court’s January 29, 2008 ruling on the other defendants’  
 3 motion to dismiss is inapplicable to Dr. Yaroshinsky’s standing arguments. *In re Connetics*  
 4 *Corp. Sec. Litig.*, 542 F. Supp. 2d 996, 1002-04 (N.D. Cal. 2008). In the January 29, 2008 Order,  
 5 the Court considered the other defendants’ argument that Plaintiff lacked standing on the injury  
 6 prong of Article III because Plaintiff did not own stock in Connetics on a day when defendants  
 7 disclosed negative information. *Id.* The Court ruled that because Plaintiff owned Connetics stock  
 8 at the time of some of Connetics disclosures and drops in the stock price, it has Article III  
 9 standing to assert other related injuries suffered by members of the class not shared by Plaintiff.  
 10 *Id.* The defendants’ argument in this regard, however, was based on claims and alleged injury  
 11 arising from false or misleading disclosures, not on claims and alleged injury based on alleged  
 12 insider trading. *See id.* Indeed, neither the Defendants argument nor the Court’s ruling addressed  
 13 this argument based on Article III standing with respect to Plaintiff’s insider trading claims. Nor,  
 14 under *Brody*, could it.

15       **C. Other Class Members’ Purported Trades Cannot Cure Plaintiff’s Lack of**  
 16       **Standing Arising From Its Failure to Trade Contemporaneously with Dr.**  
       **Yaroshinsky.**

17       The well-settled law is clear that a lead plaintiff, not another class member, must have  
 18 traded contemporaneously with each alleged insider to have standing to assert a claim against the  
 19 insider on behalf of the class. It is not sufficient, contrary to what Plaintiff maintains, that another  
 20 class member traded contemporaneously with the insider and incurred alleged injury based on  
 21 those claims. Dr. Yaroshinsky established as much in his Opening Brief based on well-settled  
 22 law that Plaintiff cannot refute. (Opening Br. at 11:3-22 (citing *Brody*, 280 F.3d at 1001;  
 23 *Neubronner*, 6 F.3d at 669-70; *O’Shea v. Littleton*, 414 U.S. 488, 493-94 (1974); *Verifone*, 784 F.  
 24 Supp. at 1489; *In re MicroStrategy, Inc. Sec. Litig.*, 115 F. Supp. 2d 620, 664 (E.D. Va. 2000); *In*  
 25 *re Waldus Sec. Litig.*, No. C92-885C, 1993 WL 121478, at \*7 (W.D. Wash. Mar. 1, 1993); *In re*  
 26 *Genentech, Inc. Sec. Litig.*, No. C-88-4038, 1989 WL 201577, at \*6 (N.D. Cal. Dec. 11, 1989).

27       Plaintiff does not and cannot overcome this well-settled law requiring that Plaintiff, not  
 28 other class members, have traded contemporaneously with Dr. Yaroshinsky in order to have

1 standing to assert insider trading claims against Dr. Yaroshinsky. First, the cases Plaintiff cites  
 2 from other circuits do not overcome the Ninth Circuit's ruling in *Brody* requiring that the named  
 3 plaintiff, not other putative class members, contemporaneously traded with the alleged insider.  
 4 *Brody*, 280 F.3d at 997; *see* Opposition Br. at 46:3-13. In *Brody*, which is controlling here, the  
 5 Ninth Circuit affirmed the district court's dismissal of a class action because the two named  
 6 plaintiffs could not plead with the requisite particularity that they (not other class members)  
 7 traded contemporaneously with the alleged insider defendants. *Brody*, 280 F.3d at 1001-02.  
 8 Indeed, "the district court held that Brody and Crawford (the named plaintiffs) are not proper  
 9 parties to assert any insider trading claims, as Brody and Crawford did not trade  
 10 contemporaneously with THC." *Id.* at 1000. Thus, the Southern District of New York's ruling  
 11 in *Openwave Systems Sec. Litig.*, which Plaintiff cites in support of its argument that its standing  
 12 can derive from other class members' purported contemporaneous trades, contradicts the Ninth  
 13 Circuit's holding in *Brody* and thus cannot be binding or controlling. *See Openwave*, 528 F.  
 14 Supp. 2d 236, 255-56 (S.D.N.Y. 2007).

15 Moreover, Plaintiff's argument based on *Middlesex Ret. Sys. v. Quest Software*, 527 F.  
 16 Supp. 2d 1164, 1196 (C.D. Cal. 2007) (referred to as "*Quest*") not only is misplaced but should  
 17 be ignored. In a more recent ruling by the *Quest* Court on the defendants' motion to dismiss the  
 18 plaintiff's Section 20A claims in a more recent amended complaint, the Court held "the class  
 19 representative must allege with specificity that it traded contemporaneously with defendants. It is  
 20 insufficient that some class members traded contemporaneously as the lead plaintiff may not  
 21 represent class members on claims it does not share." Order (1) Granting in Part and Denying in  
 22 Part Defendants' Motion to Dismiss Second Amended Complaint; (2) Ordering Discovery at 16,  
 23 *Middlesex Ret. Sys. v. Quest Software, Inc.*, No. CV 06-6863 (C.D. Cal. July 10, 2008) (citations  
 24 omitted); attached to RJD as Ex. A. Moreover, the *Quest* Court also held that, as explained in the  
 25 preceding paragraph, *Openwave* is in conflict with *Brody* and, thus, *Openwave* cannot be  
 26 followed. *Id.* at 16 n.5.<sup>2</sup> To the extent that the District of New Jersey reached a different ruling

---

27  
 28 <sup>2</sup> Even the *Quest* decision that Plaintiff cites (527 F. Supp. 2d at 1196), however, does not support the  
 proposition that Plaintiff's standing can be based on the contemporaneous trades of other class members.

1 in *In re Cendant Corp. Litig.*, 60 F. Supp. 2d 354, 378-79 (D.N.J. 1999), which Plaintiff also  
 2 cites, it would conflict with *Brody* as well and could not be followed.<sup>3</sup>

3 Thus Plaintiff's argument that contemporaneous trading by other class members is  
 4 sufficient to establish standing fails as a matter of law.

5 **D. Defendant Zak's Sales Cannot Be Imputed to Dr. Yaroshinsky and, Even if  
 6 They Could, Plaintiff did not Trade Contemporaneously with Zak.**

7 As established in Dr. Yaroshinsky's Opening Brief, Plaintiff's attempt to establish  
 8 standing as to Dr. Yaroshinsky by imputing Zak's trades to Dr. Yaroshinsky fails for two reasons.  
 9 First, Plaintiff fails to sufficiently plead facts establishing its tipper/tippee claim and, thus, it  
 10 cannot be a basis for standing as to Dr. Yaroshinsky. *See infra* Section IV. Second, even if  
 11 Plaintiff had sufficiently pled its tipper/tippee claim, Plaintiff's trades – made on April 18 and 19  
 12 – were not contemporaneous with Zak's trades.

13 **1. Plaintiff's April 18 and 19 Trades Were Not Contemporaneous with  
 14 Zak's April 13 Trades.**

15 As a court in this District has held, the purpose of the contemporaneous trading  
 16 requirement is to protect a plaintiff who was harmed by the insider and that "such harm may be  
 17 found where it appears the plaintiff might, *in fact*, have traded with the defendant." *Buban v.*  
 18 *O'Brien*, No. C 94-0331, 1994 WL 324093 (N.D. Cal. June 22, 1994) (emphasis added). This  
 19 stated purpose and limitation is consistent with (1) the Second Circuit's holding in *Wilson v.*  
 20 *Comtech Telecommunications Corp.*, which the Ninth Circuit followed in *Neubronner* in  
 21 adopting the contemporaneous trading standard – "to extend the period of liability well beyond  
 22 the time of the insider's trading simply because disclosure was never made could make the insider

---

23 As the Court made clear in its ruling, the *Lead Plaintiff* attached an exhibit to an earlier filing with the  
 24 Court in which "[Lead] Plaintiff specified the precise days when it purchased and sold Quest stock." *Id.*  
 25 (emphasis added); *see* Request for Judicial Notice ("RJN"), Ex. B (Excerpts from Second Amended  
 Complaint in *Quest*).

26 <sup>3</sup> The *Cendant* court did not reach a different ruling. In *Cendant*, the Court held that the *plaintiffs*  
 27 sufficiently pled contemporaneous trades because the "Plaintiffs have attached detailed Schedules to the  
 28 complaint which list the dates on which the plaintiffs purchased CUC and Cendant common stock and  
 those on which McLeod and other defendants sold their CUC and Cendant common stock." *Cendant*, 60  
 F. Supp. 2d at 379; *see* RJN Ex. B (Excerpts from Amended and Consolidated Complaint in *Cendant*  
 matter).

1 liable to all the world" (*Wilson*, 648 F.2d 88, 94 (2d Cir. 1988)); (2) the *Neubronner* court's  
 2 mandate that the contemporaneous trade element be strictly construed (*Neubronner*, 6 F.3d. at  
 3 669-70); and (3) the statute itself, which limits damages to the defendant's profit or loss avoided  
 4 on his trade rather than create virtually unlimited exposure to numerous possible same day (or  
 5 multiple day) traders. 15 U.S.C. § 78t-1(b)(2). This limitation on damages indicates that  
 6 Congress intended a narrow scope of the statute. *See id.*

7 Consistent with this purpose and these mandates, and as set forth in the Opening Brief,  
 8 numerous courts have unequivocally held that in order for trades to be contemporaneous, the  
 9 plaintiff's trade must be made on the *same* day as the insider's trade. (Opening Br. at 12:17-  
 10 13:17.) Indeed, Dr. Yaroshinsky cites seven such cases in his Opening Brief. *Id.* While the  
 11 *Buban* court (the Northern District court which set forth the purpose of the contemporaneous  
 12 trading requirement set forth below) did not reach the issue of whether same day trades were  
 13 necessary, it set forth two factors to consider in determining whether trades not made on the same  
 14 day are contemporaneous – (1) the overall volume of the trades on the date the defendant sold and  
 15 (2) the difference in the price at which the plaintiff purchased the stock and the price on the date  
 16 that the defendant sold. *Buban*, 1994 WL 324093, at \*3. In *Buban* the volume was 150,000  
 17 shares, the price difference was \$1.50 and the plaintiff's and the defendant's trades were three  
 18 days apart. *Id.* Under those circumstances, the Court held that "it [was] clear that plaintiff could  
 19 not have traded with defendant," and thus "there [was] no reason for the Court to apply a more  
 20 liberal standard to determine contemporaneousness." *Id.* As Dr. Yaroshinsky established in the  
 21 Opening Brief, a finding of lack of contemporaneous sales is even more compelling here given  
 22 that Plaintiff's trades were *five* days apart from Zak's trades, the volume on the date of Zak's  
 23 trades was *542,000 shares* and the price difference was *almost \$3.00*. (Opening Br. 14:20-15:7.)

24 Plaintiff ignores this extensive authority in its Opposition, including the *Buban* analysis.  
 25 Instead, Plaintiff encourages the Court to follow the broad rule apparently adopted the Central  
 26 District in *Quest* that a class action may be maintained on behalf of all persons who purchased  
 27 stock on an exchange during the period that defendants were selling that stock on the basis of  
 28 ////

1 insider information. 527 F. Supp. 2d at 1196; Opposition Br. at 8:8-14.<sup>4</sup> Plaintiff, however, fails  
 2 to respond to the bases on which Dr. Yaroshinsky already distinguished the *Quest* case in his  
 3 Opening Brief. (Opening Br. at 13 n.4.)

4 Contrary to Plaintiff's apparent contention, the rule adopted by the *Quest* court is not the  
 5 "better rule." Even the *Quest* court seems to have backed down from this rule. In its more recent  
 6 decision, the *Quest* court merely mentioned that "at least one case, purportedly following *Wilson*,  
 7 held that trading is 'contemporaneous' until disclosure of the non-public information." *Quest*,  
 8 July 10, 2008 Order at 17. The *Quest* court then did *not* apply this rule, instead finding that at  
 9 least two trades made by plaintiffs prior to disclosure were not contemporaneous. *Id.*<sup>5</sup> Moreover,  
 10 the rule Plaintiff encourages the Court to adopt flatly contradicts the Second Circuit's holding in  
 11 *Wilson* (adopted by the Ninth Circuit in *Neubronner*) that the period of liability should *not* be  
 12 extended to the time of disclosure. It also contradicts the *Neubronner* court's mandate that the  
 13 contemporaneous trade requirement be strictly construed – there could be no broader construction  
 14 than a rule that all trades through disclosure are contemporaneous. This rule also would  
 15 contradict the purpose of the contemporaneous trading requirement as set forth by the Northern  
 16 District in *Burban*. Finally, the rule contradicts the statutory intent which is demonstrated by the  
 17 limitation on disgorgement to the defendant's profit or loss avoided (15 U.S.C. § 78t-1(b)(2)) as  
 18 well as another Central District holding requiring same day trades. *In re AST Research Sec.*  
 19 *Litig.*, 887 F. Supp. 231, 233 (C.D. Cal. 1995).

20 Plaintiff's cites to cases holding that a plaintiff's trades made three days after the  
 21 defendant's trades can be considered contemporaneous are equally unpersuasive and easily  
 22 distinguished. (Opposition Br. 46 n.19.) The holding in the first case, *In re Oxford Health Plans*,  
 23

---

24 <sup>4</sup> Plaintiff also cites *In re Countrywide Financial Corp. Deriv. Litig.*, No. CV-07-06923, 2008 U.S. Dist.  
 25 LEXIS 40754 (C.D. Cal. May 14, 2008) for the proposition that courts have interpreted the  
 26 contemporaneous trading requirement in different ways. The *Countrywide* court, however, did not reach a  
 27 holding on what constitutes contemporaneous trading because it was a derivative action in which all stock  
 sold by the insiders was purchased by *Countrywide* as a part of *Countrywide*'s stock repurchase program.  
*Id.* Thus, as the *Countrywide* court stated, "the actual days on which *Countrywide* traded is not  
 significant." *Id.*

28 <sup>5</sup> While the *Quest* court found that other trades made one day and five days after a defendant's trade were  
 contemporaneous, as set forth below in discussing *Enron*, the Court should reject any such absolute rule.

1      *Inc. Sec. Litig.*, is based in part on the theory that liability should extend through the date of  
 2 disclosure. 187 F.R.D. 133, 138 (S.D.N.Y. 1999) (“Five trading days is a reasonable period  
 3 between the insider’s sale and the plaintiff’s purchase to be considered contemporaneous,  
 4 considering the last insider trades were in August 1997 and the information remained undisclosed  
 5 until October 27, 1999) (citing *In re Am. Bus. Computers Corp. Sec. Litig.*, 1994 WL 848690, \*4  
 6 (“[T]he term ‘contemporaneously’ may embrace the entire period while relevant material non-  
 7 public information remained undisclosed.”)). Plaintiff also cites *In re Eng’g Animation Sec.  
 8 Litig.*, 110 F. Supp. 2d 1183, 1196 (S.D. Iowa 2000), in which the Southern District of Iowa held  
 9 that three days constitute contemporaneous sales, citing only *Oxford*. Thus, *Eng’g Animation*  
 10 should be rejected by this Court for the same reason as *Oxford*. Finally, Plaintiff also cites *In re  
 11 Enron Corp. Sec., Deriv. & ERISA Litig.*, in which the Southern District of Texas held that “two  
 12 or three days, certainly less than a week, constitute a reasonable period to measure  
 13 contemporaneity of a defendant’s trades.” 258 F. Supp. 2d 576, 600 (S.D. Tex. 2003). To the  
 14 extent this Court is inclined not to require same day trades, the Court should reject this type of  
 15 absolute rule adopted by the *Enron* court, which does not take into account the circumstances of  
 16 each case. Rather, the Court should adopt the approach taken by the Northern District in *Buban*,  
 17 which takes into account factors (i.e., the trading volume and differential in stock prices) which  
 18 actually are determinative of whether the sales could have been contemporaneous.

19                   **2.       Zak’s Unspecified Trades Between April 24 and June 10 Were Not  
 20                   Contemporaneous with Plaintiff’s April 18 and 19 Trades.**

21                   Plaintiff’s argument that it has satisfied the contemporaneous trading standard by pleading  
 22 that Zak sold 68,000 Connetics shares on unspecified dates between April 24, 2005 and June 10,  
 23 2005 also fails. (Opposition Br. at 47:1-9.) First, Plaintiff pleads that it traded in Connetics’  
 24 stock only on April 18 and April 19. Thus, Plaintiff’s trades were made *before* Zak’s alleged  
 25 trades between April 24, 2005 and June 10, 2005. For this reason alone, as a matter of law, these  
 26 trades cannot be contemporaneous and, even if they could be imputed to Dr. Yaroshinsky (which  
 27 they cannot) would not fulfill the contemporaneous trading requirement for standing. *Verifone*,  
 28 784 F. Supp. at 1489.

1           Second, Plaintiff's argument that it did not need to plead the specific dates on which Zak  
 2 traded because it has not had access to discovery fails. (Opposition Br. at 47:6-9.) Rule 9(b) and  
 3 the Private Securities Litigation Reform Act's stringent pleading standards necessarily require  
 4 that Plaintiff plead the specific dates of Zak's trades – merely alleging that he traded on  
 5 unspecified dates over a two month period is insufficient. *See, e.g., Middlesex*, July 10, 2008  
 6 Order at 16 n.5 (applying Rule 9(b)'s particularity requirements to contemporaneous trading  
 7 requirement of Section 20A claim); *In re Wet Seal, Inc. Sec. Litig.*, 518 F. Supp. 2d 1148, 1152  
 8 (C.D. Cal. 2007) (applying the Reform Act's heightened pleading standards to claims of insider  
 9 trading under Section 10(b) and Section 20A); *Shurkin v. Golden State Vintners Inc.*, 471 F.  
 10 Supp. 2d 998, 1024, 1026 (N.D. Cal. 2006) (same); *see also* Opening Br. at 9:20-24 (citing  
 11 *Genentech*, 1989 WL 201577, at \*6). Under the Reform Act, discovery is automatically stayed  
 12 until a motion to dismiss is denied. 15 U.S.C. § 78u-4(b)(3)(B); *In re Countrywide Fin. Corp.*  
 13 *Deriv. Litig.*, 542 F. Supp. 2d 1160, 1179 (C.D. Cal. 2008) (holding that the Reform Act's  
 14 discovery stay applies to Section 10(b) and Section 20A claims). Plaintiff does not and cannot  
 15 cite any authority that the discovery stay excuses the Reform Act's requirement that it plead its  
 16 Section 10(b) and Section 20A claims with particularity, including the specific dates on which  
 17 Zak allegedly traded. The reverse is true. Indeed, the only case Plaintiff cites in support of its  
 18 position regarding discovery is *Neubronner*, which was decided *prior* to enactment of the Reform  
 19 Act.<sup>6</sup> For this reason as well, Zak's sales between April 24, 2005 and June 10, 2005 cannot be  
 20 imputed to Dr. Yaroshinsky for purposes of meeting the contemporaneous trading requirement.  
 21 Moreover, given that Plaintiff's alleged trades were *before* Zak's alleged trades between April 25,  
 22 2005 and June 10, 2005, the Court need not reach this issue.

23

---

24           <sup>6</sup> Plaintiff also cites *Countrywide* and *In re Qwest Communs. Int'l Sec. Litig.*, 396 F. Supp. 2d 1178, 1201  
 25 (D. Colo. 2004) in support of their argument that they do not have to plead the specific dates of Zak's  
 26 trades. In *Countrywide*, however, the issue was whether the Plaintiff needed to plead with particularity the  
 27 dates that the Plaintiff (*Countrywide*) traded, not the dates on which the defendants traded. *Countrywide*,  
 28 2008 U.S. Dist. LEXIS 40754, at \*82. Moreover, for the reasons cited in footnote 4 above, the  
*Countrywide* Court held that, unlike this case, "the actual days on which *Countrywide* traded its stock is  
 not significant." *Id.* Plaintiff's reliance on *Qwest* also is misplaced. In *Qwest*, the "plaintiffs ha[d]  
 alleged that the individual defendants traded *Qwest* securities on a variety of *specified* dates during the  
 class period." *Qwest*, 396 F. Supp. 2d at 1201 (emphasis added).

1           For these reasons, Plaintiff has failed to establish that it has standing to assert its Section  
 2 10(b) and Rule 20A claims against Dr. Yaroshinsky. Dr. Yaroshinsky's motion to dismiss,  
 3 therefore, should be granted *with prejudice* without further analysis.

4 **III. THE COMPLAINT FAILS TO PLEAD A STRONG INFERENCE OF SCIENTER**

5           Even if Plaintiff had established it has standing, which it has not, Dr. Yaroshinsky's  
 6 Opening Brief establishes that the Complaint must be dismissed for another reason – the  
 7 Complaint fails to plead specific facts supporting a strong inference of scienter. Opening Br. at  
 8 9:15-12:13. As set forth in the Opening Brief, the U.S. Supreme Court recently held that in order  
 9 to plead a strong inference of scienter, the inference from a plaintiff's allegations must be  
 10 "powerful," "cogent," and "compelling" – it is not enough that the inference be "reasonable" or  
 11 "permissible." *Id.* at 5:28-6:3 (citing *Tellabs v. Makor Issues & Rights, Ltd.*, 127 S. Ct. 2499,  
 12 2510 (2007)). Moreover, the inference of scienter "must be more than merely 'reasonable' or  
 13 'permissible'" – it must be cogent . . . and at least as compelling as any plausible inference one  
 14 could draw from the facts alleged." *Id.* at 5:14-17.

15           Plaintiff does not attempt to show how the pleadings in the Complaint satisfy the *Tellabs*  
 16 standard and fails to even mention *Tellabs* with respect to Dr. Yaroshinsky. See Opposition Br. at  
 17 6:5-8:16. First, Plaintiff does not respond to Dr. Yaroshinsky's showing that Plaintiff failed to  
 18 plead any inference of scienter, let alone a strong inference, because the Complaint does not plead  
 19 with particularity that Dr. Yaroshinsky received any material non-public information. (Opening  
 20 Br. 16:7-17:2.) This motion to dismiss may be granted on this ground alone.

21           Second, Plaintiff does not adequately respond to Dr. Yaroshinsky's showing in the  
 22 Opening Brief that, given Connexis' April 26, 2005 press release and earnings call (Opening Br.  
 23 at 10:14-11:8), the most cogent and compelling inference is that by April 26, 2005 Dr.  
 24 Yaroshinsky believed that he did not possess any material non-public information and that he  
 25 could trade without violating the securities laws – i.e., he did not act with scienter. Plaintiff's  
 26 only response on point is to argue that this cannot be the most compelling inference because the  
 27 Court noted in its earlier ruling on the other defendants' motion to dismiss that it is inclined to  
 28 agree with Plaintiff that additional information should have been disclosed in the April 25, 2005

1 disclosures. (Opposition Br. at 49:1-6.) Anticipating Plaintiff's position, Dr. Yaroshinsky  
 2 addressed this issue in his Opening Brief, explaining that the issue is not whether the April 26,  
 3 2005 disclosures were complete under the complex securities laws. (Opening Br. at 17 n.6.)  
 4 Rather, the issue is whether Dr. Yaroshinsky, who is a scientist who was not involved in drafting  
 5 the press release and did not participate in the conference call, *thought* all material non-public  
 6 information had been disclosed in the April 26, 2005 press release and conference call. *Id.*  
 7 Plaintiff does not and cannot allege facts showing that Dr. Yaroshinsky had or believed he had  
 8 material non-public information in light of those disclosures. It would be unreasonable to expect  
 9 Dr. Yaroshinsky to differentiate between a full and partial disclosure where the Company has  
 10 gone out of its way to make disclosures about the FDA contact and it is common knowledge that  
 11 such disclosures by public companies are thoroughly vetted with legal counsel. Thus, Plaintiff  
 12 does not and cannot establish that an equally or more compelling inference is that Dr.  
 13 Yaroshinsky, who is a scientist, not a securities lawyer, knew that the April 26, 2005 disclosures  
 14 may not have been complete and that he had any material non-public information. *See id.*<sup>7</sup>

15 The remainder of Plaintiff's response to Dr. Yaroshinsky's showing that Plaintiff has  
 16 failed to sufficiently plead scienter is nothing more than a laundry list of allegations scattered  
 17 through the Complaint, coupled with the conclusory statement that they sufficiently plead a  
 18 strong inference of scienter. Opposition Br. at 48:9-27. Plaintiff cites no authority for its  
 19 conclusory statements and, under *Tellabs*, fails to establish that these conclusory statements  
 20 sufficiently plead a strong inference of scienter.<sup>8</sup>

21 Because the Complaint fails to plead a strong inference of scienter, dismissal is mandatory

22  
 7 None of Plaintiff's other purported bases for attempting to refute the compelling inference that Dr.  
 23 Yaroshinsky thought all material non-public information had been disclosed relate to this inference. First,  
 24 Connectics' trading ban was imposed on April 13, two weeks before the April 26, 2005 disclosures, and  
 25 thus is unrelated to what Dr. Yaroshinsky believed following the April 26, 2005 disclosures. Second, Dr.  
 26 Yaroshinsky's trades on April 27, 2005 – after the April 26, 2005 disclosures – is consistent with the  
 27 compelling inference that Dr. Yaroshinsky believed all material non-public information had been  
 28 disclosed. Finally, the purported accounts registered in his mother-in-laws name were created before the  
 April 26, 2005 disclosures, rendering them meaningless to the compelling inference that Dr. Yaroshinsky  
 believed all material non-public information was disclosed on April 26, 2005.

8 Plaintiff also fails to respond to Dr. Yaroshinsky's showing that the confidential witnesses set forth in the  
 Complaint and statements made in Dr. Yaroshinsky's answer to the SEC Complaint do not plead a strong  
 inference of scienter. (Opening Br. at 18:1-19:4.)

1 for this independent reason as well. 15 U.S.C. § 78u-4(b)(3)(A).

2 **IV. PLAINTIFF DID NOT STATE A CLAIM FOR TIPPER/TIPPEE LIABILITY**

3 In addition to Plaintiff's failure to plead contemporaneous trades and scienter, as  
 4 established in the Opening Brief, Plaintiff's purported tipper/tippee claim fails for several  
 5 additional reasons almost all of which Plaintiff fails to address in its Opposition. First, Plaintiff  
 6 fails to address Dr. Yaroshinsky's showing that the tipper/tippee theory of liability fails because it  
 7 is asserted only in Plaintiff's Section 20A cause of action and not in Plaintiff's predicate Section  
 8 10(b) cause of action. (Opening Br. at 19:27-20:2.) Plaintiff also ignores Dr. Yaroshinsky's  
 9 showing that Plaintiff fails to meet the Reform Act's heightened pleading standards with respect  
 10 to its tipper/tippee theory of liability, instead pleading it in only the most conclusory manner at  
 11 the end of the Complaint. (Opening Br. at 20:3-13.) Plaintiff's claims against Dr. Yaroshinsky  
 12 for tipper/tippee liability may be dismissed on these grounds alone.

13 Moreover, Plaintiff fails to adequately respond to Dr. Yaroshinsky's showing that the  
 14 mere pleading in the Complaint that Zak was Dr. Yaroshinsky's "friend" and "former neighbor"  
 15 does not constitute the requisite particularized facts to plead that Dr. Yaroshinsky directly or  
 16 indirectly gained a personal benefit. (Opening Br. at 20:14-21:4.) Instead, Plaintiff cites cases  
 17 setting forth what a plaintiff must *prove* to establish a direct or indirect personal benefit, which  
 18 can be *proof* that the defendant intended to benefit the alleged tippee or *proof* of a gift to a trading  
 19 relative or friend. (Opposition Br. at 47:16-21.) However, a showing of an intent to benefit or a  
 20 special relationship based on evidence is separate and distinct from what facts a plaintiff must  
 21 *plead* in its complaint to sufficiently state a claim of a direct or indirect benefit. Moreover,  
 22 Plaintiff does not and cannot cite any authority that merely making the conclusory allegation that  
 23 a purported tipper and tippee are friends or that the purported tipper intended to benefit the tippee  
 24 is sufficient, especially under the heightened pleading standards of the Reform Act which requires  
 25 that each element be plead with particularity. Indeed, every case which Plaintiff cites involves a  
 26 case filed by the SEC, which, unlike the Plaintiff in this case, is *not* subject to the stringent  
 27 pleading standards of the Reform Act. *See* 15 U.S.C. § 78u-4(a)(1). Thus, Plaintiff's authority  
 28 cited in its Opposition fails to refute Dr. Yaroshinsky's showing that Plaintiff failed to sufficiently

plead its claim based on tipper/tippee liability.

Contrary to Plaintiff’s position, the law in the Northern District is that conclusory allegations of personal benefit, such as Plaintiff’s, are insufficient and the court need not indulge in any unwarranted inference. (Opening Br. at 20:14-21:4 (citing *Shurkin*, 471 F. Supp. 2d at 1025).) Plaintiff does not and cannot respond. For these reasons, Plaintiff’s attempt to salvage its case based on a purported theory of tipper/tippee liability fails.

**V. THE SECTION 20A CLAIM MUST BE DISMISSED ON OTHER GROUNDS**

In the Opposition Brief, Plaintiff also fails to refute the additional bases on which its Section 20A claim should be dismissed. First, Plaintiff fails to adequately respond to Dr. Yaroshinsky’s showing that the Section 20A claim must be dismissed because Plaintiff has failed to sufficiently plead its Section 10(b) claim, which is the predicate violation for the Section 20A claim. Rather, Plaintiff merely states that it has sufficiently pled its Section 10(b) claim without establishing as much. (Opposition Br. at 49:16-22.) This response is wholly inadequate. The same is true with respect to Dr. Yaroshinsky’s showing that the Complaint must be dismissed because Plaintiff does not seek relief available under Section 20A, which is limited to disgorgement. (Opening Br. at 19:14-25.) Plaintiff’s only response is to state that it is seeking disgorgement. (Opposition Br. at 49:23-26.) Since this request is not pled in the Complaint, Plaintiff fails to provide a cite in support of its position. Moreover, Plaintiff’s litany of damages, which include compensatory damages and/or rescission, interest, and attorneys’ fees and costs, are impermissible forms of relief under Section 20A and should be stricken.

## VI. CONCLUSION

Plaintiff fails to state a claim against Dr. Yaroshinsky and the Second Amended Complaint should be dismissed with prejudice as to Dr. Yaroshinsky.

Dated: July 18, 2008

Respectfully Submitted,  
DLA PIPER US LLP

By /s/ Gerard A. Trippitelli  
GERARD A. TRIPPITELLI  
Attorneys for Defendant  
ALEXANDER YAROSHINSKY